PB713B-pCMV-MITD-NeoMini-T2A-tCD19-WPRE
(Plasmid
#174610)
-
PurposePiggyBack transposon expressing a fusion of a tandem minigene antigens in KRAS, BRAF and CMV fused to an endosomal targeting sequence and translationally linked to human truncated CD19
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 174610 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backboneMP71
-
Vector typeMammalian Expression
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberUnknown
Gene/Insert
-
Gene/Insert namehuman CD19, antigen minigene
-
SpeciesH. sapiens (human)
Resource Information
-
Supplemental Documents
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
PB713B-pCMV-MITD-NeoMini-T2A-tCD19-WPRE was a gift from Stanley Riddell (Addgene plasmid # 174610 ; http://n2t.net/addgene:174610 ; RRID:Addgene_174610) -
For your References section:
A therapeutic cancer vaccine delivers antigens and adjuvants to lymphoid tissues using genetically modified T cells. Veatch JR, Singhi N, Srivastava S, Szeto JL, Jesernig B, Stull SM, Fitzgibbon M, Sarvothama M, Yechan-Gunja S, James SE, Riddell SR. J Clin Invest. 2021 Aug 16;131(16):e144195. doi: 10.1172/JCI144195. 10.1172/JCI144195 PubMed 34396986